Agios制药

AGIO NASDAQ
49.13
-1.65
-3.25%
交易中 14:04 06/24 EDT
开盘
50.55
昨收
50.78
最高
50.84
最低
48.78
成交量
15.35万
成交均量(3M)
51.92万
52周最高
96.85
52周最低
41.63
换手率
0.26%
市值
28.84亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Agios制药 AGIO股票价格,Agios制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company's cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its rare genetic metabolic disorder (RGD), programs, AG-348, targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. Pyruvate kinase deficiency is a rare disorder that often results in severe hemolytic anemia due to inherited mutations in the pyruvate kinase enzyme within red blood cells.
展开 >

最近浏览

名称
价格
涨跌幅